Why GitLab Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 04 2024
0mins
Source: Benzinga
GitLab Financial Performance: GitLab Inc. shares surged 16.8% in pre-market trading after reporting second-quarter earnings of 15 cents per share, exceeding analyst expectations by 50%, and revenue of $182.6 million, surpassing estimates.
Stock Movements: Several stocks saw significant movements in pre-market trading, with WiSA Technologies gaining 63.2% and Athira Pharma dropping 72.7% following disappointing clinical trial results.
Analyst Views on OGEN
About OGEN
Oragenics, Inc. is a development-stage company. It is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. It focuses on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including drug candidates for treating mild traumatic brain injury (mTBI or Concussion), and for treating Niemann Pick Disease Type C (NPC), and proprietary powder formulation and an intranasal delivery device. Its lead product, ONP-002, is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. It is also focused on developing medical products that treat brain related illnesses and diseases (the Neurology Assets). Its other product candidate, ONP-001, is in its early stage and clinical trials.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
